{"title":"Celgene获得VentiRx癌症合作的收购选择权","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I10.1825","DOIUrl":null,"url":null,"abstract":"Celgene has formed a global collaboration with the virtual company VentiRx Pharmaceuticals to fund Phase II trials of VentiRx’s TLR8 (Toll-like receptor 8) agonist VTX-2337 in ovarian and head-and-neck cancers. Celgene will provide US$35 M upfront for further development of the drug through predefined clinical endpoints and in return retains an exclusive option to acquire VentiRx at a predetermined price. VentiRx is also eligible to receive additional funding during the option period, including a potential equity investment by Celgene. VentiRx in-licensed Array BioPharma’s TLR8 programme in 2007.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"100 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Celgene Gains Buyout Option with VentiRx Cancer Collaboration\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I10.1825\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Celgene has formed a global collaboration with the virtual company VentiRx Pharmaceuticals to fund Phase II trials of VentiRx’s TLR8 (Toll-like receptor 8) agonist VTX-2337 in ovarian and head-and-neck cancers. Celgene will provide US$35 M upfront for further development of the drug through predefined clinical endpoints and in return retains an exclusive option to acquire VentiRx at a predetermined price. VentiRx is also eligible to receive additional funding during the option period, including a potential equity investment by Celgene. VentiRx in-licensed Array BioPharma’s TLR8 programme in 2007.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"100 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-10-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I10.1825\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I10.1825","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Celgene Gains Buyout Option with VentiRx Cancer Collaboration
Celgene has formed a global collaboration with the virtual company VentiRx Pharmaceuticals to fund Phase II trials of VentiRx’s TLR8 (Toll-like receptor 8) agonist VTX-2337 in ovarian and head-and-neck cancers. Celgene will provide US$35 M upfront for further development of the drug through predefined clinical endpoints and in return retains an exclusive option to acquire VentiRx at a predetermined price. VentiRx is also eligible to receive additional funding during the option period, including a potential equity investment by Celgene. VentiRx in-licensed Array BioPharma’s TLR8 programme in 2007.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
